Collectively, these observations position TMEM106A as a companion biomarker candidate for risk stratification and PD‐1–axis nomination in IDH‐wildtype glioma, with cytokine‐pathway co‐targeting and mutant‐p53 strategies as prioritized avenues. This evidence concerns the gene TP53 and central nervous system cancer.